TiGenix NV/SA (TiGenix) and its subsidiaries TiGenix Inc. and TC CEF LLC. is a Belgium-based biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. The Company is exploiting the power of regenerative medicine for the development of durable treatments, validated through controlled clinical studies, for these indications. TiGenix is located in Leuven and was founded as a spin-off of the Catholic University of Leuven and the University of Ghent. TiGenix is developing a portfolio of products that addresses specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction severely affecting the mobility and functioning of patients. During the fiscal year ended December 31, 2009, the Company acquired Orthomimetics Ltd.
Current Team (6)Update
Funding Rounds (3) - $37.5MUpdate
Board Members and Advisors (3)Update
Haasrode Researchpark 1724
Romeinse straat 12 bus 2